HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively:A Perspective Cohort Study

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorPeking University First Hospital

About this trial

This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.

Eligibility criteria

Qualifiers

pathological diagnose of UTUC;

Met more than muscle-invasion stages(pT2+) or lymph nodes metastasis.

Disqualifiers

Patients with early-local stages (pTa/T1/Tis) without LNM+ and those with incomplete pathologic and prognostic information were excluded

Trial design

Treatments tested in this trial

  • Chemotherapy
  • Immunotherapy
  • ADC
  • Chemotherapy combined with immunotherapy

Treatment groups

200 Participants
are divided into 4 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Peking University First Hospital

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator

Peking University Third Hospital

Collaborator

Fujian Provincial Hospital

Collaborator